Chinese quality control indices for standardized diagnosis and treatment of gastric cancer(2022 edition)

Gastric cancer is one of the most common malignancies of the digestive system,and the number of deaths continues to increase.The standardized management of the diagnosis and treatment of gastric cancer is challenging due to the great differences in the diagnosis and treatment of gastric cancer in different regions.The Gastric Cancer Expert Committee of the National Cancer Quality Control Center(NCQCC)identified a lack of authoritative quality control standards as an opportunity to utilize its multidisciplinary membership to improve the standardized diagnosis and treatment of gastric cancer.The Gastric Cancer Expert Committee of the NCQCC aims to promote quality control and national standardization,uniformity,and normalization of gastric cancer diagnosis and treatment,which ultimately improved the survival rate and quality of life of gastric cancer patients.A panel of experts with gastrointestinal cancer surgery,gastrointestinal cancer medicine,medical imaging,pathology and radiotherapy were drawn together and determined the quality control standards for the standardized diagnosis and treatment of gastric cancer.The authors then utilized a modified Delphi approach to generate consensus recommendations.

Chinese quality control indices for standardized diagnosis and treatment of renal cancer(2022 edition)

Renal cancer is one of the most common malignancies of the urinary system,and the number of deaths continues to increase.The standardized management of the diagnosis and treatment of renal cancer is challenging due to the great differences in the diagnosis and treatment of renal cancer in different regions.The Renal Cancer Expert Committee of the National Cancer Quality Control Center(NCQCC)identified a lack of authoritative quality control standards as an opportunity to utilize its multidisciplinary membership to improve the standardized diagnosis and treatment of renal cancer.The Renal Cancer Expert Committee of the NCQCC aims to promote quality control and national standardization,uniformity,and normalization of renal cancer diagnosis and treatment,which ultimately improved the survival rate and quality of life of renal cancer patients.A panel of experts with renal cancer surgery,renal cancer medicine,medical imaging,pathology and radiotherapy were drawn together and determined the quality control standards for the standardized diagnosis and treatment of renal cancer.The Indices includes 20 items that cover all key areas in the diagnosis and treatment of renal cancer,such as standard diagnosis,surgery treatment,systemic treatment,and prognostic evaluation.

Quality control indices for standardized diagnosis and treatment of esophageal cancer in China (2022 edition)

Esophageal cancer(EC)is particularly common in China.With the continuing progress of multi-disciplinary therapy including early screening,minimally invasive techniques,radiotherapy and chemotherapy,the 5-year survival of EC has been improved in China.However,there are considerable disparities in the diagnosis and treatment quality among different regions.The Esophageal Cancer Expert Committee of the National Cancer Quality Control Center(NCQCC)considers a set of authoritative quality control standards as an opportunity to eliminate the disparities and improve the overall survival and quality of life of EC.To further promote the quality control for standardized diagnosis and treatment of EC,the National Cancer Center commissioned the Esophageal Cancer Quality Control Expert Committee to draft and formulate the Chinese Quality Control Indices for Standardized Diagnosis and Treatment of Esophageal Cancer(2022 edition).The Indices includes 21 items that cover all key areas in the diagnosis and treatment of esophageal cancer,such as medical oncology,radiation oncology,endoscopy,and pathology.

Towards efficiency in rare disease research： what is distinctive and important？

Characterized by their low prevalence, rare diseases are often chronically debilitating or life threatening. Despite their low prevalence, the aggregate number of individuals suffering from a rare disease is estimated to be nearly 400 million worldwide.Over the past decades, efforts from researchers, clinicians, and pharmaceutical industries have been focused on both the diagnosis and therapy of rare diseases. However, because of the lack of data and medical records for individual rare diseases and the high cost of orphan drug development, only limited progress has been achieved. In recent years, the rapid development of next-generation sequencing(NGS)-based technologies, as well as the popularity of precision medicine has facilitated a better understanding of rare diseases and their molecular etiology. As a result, molecular subclassification can be identified within each disease more clearly, significantly improving diagnostic accuracy. However, providing appropriate care for patients with rare diseases is still an enormous challenge. In this review, we provide a brief introduction to the challenges of rare disease research and make suggestions on where and how our efforts should be focused.

Current status of immunotherapy in gastric cancer

Gastric cancer is one of the most common cancer with high mortality and morbilidity in East Asia,especially in China.In recent year,new treatment strategies for gastric cancer have developed.Immune check point inhibitors(ICIs)have been detected as a new standard treatment in Gastric cancer,which helped to improve the prognosis of patients with gastric cancer.Attempts to combine immunotherapy have become one of the research focuses.In this article,application of immunotherapy in neoadjuvant therapy and translational treatment of gastric cnacer are reviewed.Which is expected to be a reference for comprehensive treatment plan of accurate treatment methods for gastric cancer patients.In order to provide experiences and reference to develop individualized treatment of gastric cancer in clinical practice.